Protalix BioTherapeutics Investor Relations Material
Latest events
Q3 2024
Protalix BioTherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Protalix BioTherapeutics Inc
Access all reports
Protalix BioTherapeutics Inc. is a biopharmaceutical company focusing on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. This technology enables the company to produce proteins with clinically improved profiles and to develop a pipeline of proprietary therapeutic proteins aimed at established pharmaceutical markets. Additionally, the company is developing other products, including treatments for cystic fibrosis and Fabry Disease, utilizing its platform to manufacture complex proteins, antibodies, and vaccines. The company is headquartered in Carmiel, Israel, and its shares are listed on the NYSE.
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
PLX
Country
🇺🇸 United States